CHAIN features in Genetic Engineering & Biotechnology News (GEN)
https://www.genengnews.com/insights/synthetic-biology-seizes-new-ground-in-healthcare/
read moreCHAIN Biotechnology Ltd was founded by Dr Edward Green in 2014 to develop new Clostridium-based microbial technology for high value healthcare products. CHAIN produces novel live biotherapeutic products (LBPs) for chronic gut-related diseases, such as Inflammatory Bowel Disease (IBD).
At the heart of CHAIN’s unique therapeutic platform is a suite of underpinning technologies including a Clostridia culture collection, a proprietary set of plasmid vectors, synthetic biology tools for advanced metabolic engineering, and an advanced in-vivo delivery mechanism using Clostridium.
Status current
Associated Fund UK Innovation & Science Seed Fund
Sector Medical / Biotechnology
Website chainbiotech.com/
https://www.genengnews.com/insights/synthetic-biology-seizes-new-ground-in-healthcare/
read moreCHAIN has worked closely with the University of Nottingham since our beginning, and it...
read moreOxford, UK – 2nd July 2019 Oxford Vacmedix UK Limited (OVM), the UK-based biopharma...
read moreCHAIN’s drug delivery platform and lead product, β-hydroxybutyrate, is highlighted in a new report ‘Catalysing Investment...
read moreMARLOW & NOTTINGHAM, UK. — April 8, 2019 – UK microbiome therapeutics company CHAIN...
read moreCHAIN has been awarded two grants to support its therapeutic delivery platform from Innovate...
read moreUpdate your browser to view this website correctly.Update my browser now